The public markets exhibit extreme short-termism. The immediate post-deal performance of follow-on financings heavily influences investor sentiment for subsequent deals. Poor performance one week empowers insiders to demand steeper discounts the next, creating a volatile feedback loop.

During market downturns, biotech companies lose the ability to raise capital simply when it's convenient. Financing becomes tied to specific events. The key is timing a fundraise immediately before or after the release of significant clinical data that de-risks the company and attracts new investors.

Summit Therapeutics' decision to pull its $500M offering illustrates a key risk. The public knowledge that the company needs capital but was unhappy with the price creates an overhang, as investors may now wait for a future, potentially discounted, financing event, putting downward pressure on the stock.

Successful clinical data is being immediately rewarded with significant capital, indicating a robust funding market. Xenon and Dianthus both raised over $700 million following positive trial results, demonstrating strong investor appetite to fund de-risked assets and reward companies that deliver on clinical promises.

Instead of raising money immediately after positive trial data, Rhythm waited. This allowed sell-side analysts time to understand the results, build financial models, and educate investors. This patience resulted in a stock that coalesced at a much higher valuation, maximizing the capital raise.

In a capital-constrained market, positive clinical data can trigger a stock drop for biotechs with insufficient cash. The scientific success highlights an immediate need for a highly dilutive capital raise, which investors price in instantly. Having over two years of cash is now critical to realizing value.

Biotech leaders shouldn't "fall on their knife" to avoid dilution. The objective isn't survival; it's financing the company to a value-changing event. No company fails from dilution, but many fail from being underfunded to reach a key milestone.

Despite a strong year for biotech, investors are showing signs of fatigue. This leads them to sell stocks immediately after positive news and financing rounds to lock in gains before year-end, rather than letting positive momentum build further.

A clear fundraising playbook is emerging for successful biotechs: release strong clinical data, experience a significant share price increase, and immediately launch a follow-on offering that gets substantially upsized. Xenon leveraged a 50% stock bump to turn a proposed $500M offering into nearly $750M, demonstrating a powerful strategy in the current market.